Lion Biotechnologies, Inc. (LBIO) Receives Consensus Recommendation of “Buy” from Analysts

Lion Biotechnologies, Inc. (LBIO) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Lion Biotechnologies, Inc. (NASDAQ:LBIO) have been given a consensus rating of “Buy” by the seven analysts that are currently covering the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $19.30.

LBIO has been the subject of several recent research reports. FBR & Co set a $18.00 target price on shares of Lion Biotechnologies and gave the stock a “buy” rating in a research report on Wednesday, January 11th. Roth Capital restated a “buy” rating and set a $15.00 price target on shares of Lion Biotechnologies in a report on Monday, November 28th. Jefferies Group LLC restated a “buy” rating and set a $13.00 price target on shares of Lion Biotechnologies in a report on Monday, November 7th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a report on Friday, November 4th. Finally, Zacks Investment Research upgraded shares of Lion Biotechnologies from a “sell” rating to a “hold” rating in a report on Wednesday, October 26th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LBIO. Victory Capital Management Inc. bought a new position in Lion Biotechnologies during the third quarter worth $19,234,000. BlackRock Advisors LLC boosted its position in Lion Biotechnologies by 1,891.9% in the third quarter. BlackRock Advisors LLC now owns 1,281,870 shares of the biotechnology company’s stock worth $10,550,000 after buying an additional 1,217,515 shares during the last quarter. Franklin Resources Inc. boosted its position in Lion Biotechnologies by 55.6% in the second quarter. Franklin Resources Inc. now owns 3,388,500 shares of the biotechnology company’s stock worth $26,467,000 after buying an additional 1,210,500 shares during the last quarter. Perceptive Advisors LLC boosted its position in Lion Biotechnologies by 29.6% in the second quarter. Perceptive Advisors LLC now owns 3,611,976 shares of the biotechnology company’s stock worth $29,257,000 after buying an additional 824,720 shares during the last quarter. Finally, BlackRock Group LTD boosted its position in Lion Biotechnologies by 5,129.8% in the third quarter. BlackRock Group LTD now owns 688,872 shares of the biotechnology company’s stock worth $5,669,000 after buying an additional 675,700 shares during the last quarter. Hedge funds and other institutional investors own 75.95% of the company’s stock.

Shares of Lion Biotechnologies (NASDAQ:LBIO) traded down 0.70% on Friday, hitting $7.10. 38,448 shares of the stock traded hands. The stock has a 50 day moving average price of $7.11 and a 200-day moving average price of $7.59. Lion Biotechnologies has a 52 week low of $4.24 and a 52 week high of $9.58. The stock’s market cap is $440.81 million.

About Lion Biotechnologies

Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.

Related posts

Leave a Comment